This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Pharma Stock Roundup: FDA Okays AZN's Capivasertib & MRK's Keytruda Expanded Use
by Kinjel Shah
FDA approves AstraZeneca's (AZN) new breast cancer drug, Truqap, and the expanded use of Merck's (MRK) Keytruda in a gastric cancer indication
AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast Cancer
by Zacks Equity Research
AstraZeneca's (AZN) capivasertib gets approval in combination with Faslodex for HR-positive, HER2-negative metastatic breast cancer.
Zacks Investment Ideas feature highlights: Lululemon, Apple, Tesla, Novo Nordisk and DraftKings
by Zacks Equity Research
Lululemon, Apple, Tesla, Novo Nordisk and DraftKings have been highlighted in this Investment Ideas article.
3 Industry Titans Benefitting from Mega Trends
by Andrew Rocco
What do stretchy pants, fat-loss drugs, and sports betting have in common? Each of these is powering some of the strongest mega-trends on Wall Street.
Pfizer's (PFE) New Products May Drive Long-Term Sales Growth
by Kinjel Shah
Though Pfizer's (PFE) revenues from COVID products are declining sharply, the launch of some key non-COVID products in 2023 is expected to drive long-term sales and profit growth.
Catalent (CTLT) Up on Encouraging Pre-Filled Syringe Potential
by Zacks Equity Research
Catalent (CTLT) expects the demand for its pre-filled syringes to improve going forward. The company anticipates the majority of its pre-filled syringe production capacity to be booked until fiscal 2026.
AstraZeneca's (AZN) Imfinzi Early-Stage Lung Cancer Study Fails
by Zacks Equity Research
AstraZeneca's (AZN) PACIFIC-2 study on Imfinzi fails to achieve statistical significance for the primary endpoint of progression-free survival.
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, J&J and AbbVie
by Zacks Equity Research
Eli Lilly, Novo Nordisk, J&J and AbbVie are part of the Zacks Industry Outlook article.
Novo Nordisk's (NVO) Wegovy Positive in Cardiovascular Study
by Zacks Equity Research
Novo Nordisk's (NVO) obesity drug Wegovy shows potential in cardiovascular study beyond the benefits of associated weight loss.
4 Large Drug Stocks Likely to Sail Through Industry Woes
by Kinjel Shah
Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), J&J (JNJ) and AbbVie (ABBV) are worth retaining in your portfolio.
Take the Zacks Approach to Beat the Market: Shopify, American Eagle, Microsoft in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
AstraZeneca (AZN) Buys Global Rights to Oral Obesity Candidate
by Zacks Equity Research
To cash in on the rising demand for obesity drugs, AstraZeneca (AZN) in-licenses exclusive rights to ECC5004, a novel oral GLP-1RA therapy, from private Chinese biotech Eccogene.
AstraZeneca (AZN) Beats on Q3 Earnings & Sales, Ups 2023 View
by Zacks Equity Research
AstraZeneca (AZN) beats third-quarter estimates for earnings and sales. The company raises its sales and EPS guidance for 2023.
Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue Hike
by Zacks Equity Research
Prothena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY.
Eli Lilly (LLY) Q3 Earnings & Sales Top, EPS View Cut, Stock Up
by Zacks Equity Research
Eli Lilly (LLY) beats third-quarter estimates for earnings as well as sales. It cut its earnings guidance for 2023 on charges related to acquisitions and collaboration deals.
Novo Nordisk (NVO) Q3 Earnings and Sales Beat, 2023 View Up
by Zacks Equity Research
Novo Nordisk (NVO) reports encouraging third-quarter results, beating both earnings and sales estimates, driven by strong sales of diabetes and obesity care products. Management raises 2023 guidance.
Looking for a Growth Stock? 3 Reasons Why Novo Nordisk (NVO) is a Solid Choice
by Zacks Equity Research
Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Should You Buy Novo Nordisk (NVO) Ahead of Earnings?
by Zacks Equity Research
Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Novo Nordisk (NVO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Novo Nordisk (NVO) is likely to outperform third-quarter 2023 estimates, driven by increased Diabetes and Obesity Care product sales despite severe rivalry and pricing pressure in the United States.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Beat the Market the Zacks Way: Novo Nordisk, Lifeway Foods, Casey's in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
The Zacks Analyst Blog Highlights Microsoft, Novo Nordisk A/S and Lowe's
by Zacks Equity Research
Microsoft, Novo Nordisk A/S and Lowe's are included in this Analyst Blog.
Q3 Earnings Season Scorecard - Earnings Growth Turns Positive
by Sheraz Mian
Today's Research Daily features real-time scorecard of the Q3 earnings season in addition to Microsoft (MSFT), Novo Nordisk (NVO), Lowe's (LOW) and others.
Novo Nordisk (NVO) Stock Moves -0.09%: What You Should Know
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $97.43, marking a -0.09% move from the previous day.